Purpose of Review Nonmammalian comparative animal models are important not only to gain fundamental evolutionary understanding of the complex interactions of tumors with the immune system but also to better predict the applicability of novel immunotherapeutic approaches to humans. After reviewing recent advances in developing alternative models, we focus on the amphibian Xenopus laevis and its usefulness in deciphering the perplexing roles of MHC class I-like molecules and innate (i)T cells in tumor immunity. Recent Findings Experiments using MHC-defined inbred and cloned animals, tumor cell lines, effective reagents, sequenced genomes, and adapted gene editing techniques in Xenopus, have revealed that the critical involvement of class I-like molecules and iT cells in tumor immunity has been conserved during evolution. Summary Comparative studies with the X. laevis tumor immunity model can contribute to the development of better and more efficient cancer immunotherapies.
Introduction
The formation of tumors or tumorigenesis is a process widespread across all multicellular organisms [1] . Both benign tumors and malignant cancers are a group of complex diseases in which transformed cells uncontrollably proliferate. Through a multistep process of tumor formation, abnormal cells acquire traits that enable them to sustain their growth and resist signals that would otherwise prevent it [2] . In the case of cancers, the deregulated cells often spread or metastasize elsewhere in the body. Apart from the intrinsic molecular barriers against tumors such as DNA repair mechanisms, tumor suppressor genes, and programed cell death, immunity has recently emerged as a key component influencing tumorigenesis [3] [4] [5] .
Following a century of heated debate, the significance of the immune system in the detection and eradication of transformed cells was validated by a series of studies with immunodeficient mice. In the mid-1990s, it was demonstrated that chemically induced cancers developed more frequently and rapidly in mice deficient in crucial elements of the immune system such as interferon gamma, perforin, or recombination-activating genes (reviewed in [6] ). In human, multiple clinical studies have correlated the increased risk of certain cancers in organ transplant recipients who were routinely immunosuppressed to avoid graft rejection [7] . Ever since the role of the immune system in surveillance against tumors was confirmed, a concerted goal in the tumor immunity field has been to identify the key immune players and to harness their therapeutic potential against cancer. Pioneering immunotherapies, such as those that release cytotoxic T cells from suppression, have achieved considerable success because their benefits have been shown even in advanced cancer patients [8] . More recently, novel approaches including adoptive cell transfer of engineered T cells transformed in vitro to express chimeric antigen receptors (CAR) or using antibodies that block the checkpoint inhibitors such as Programmed cell death protein 1 (PD-1) have encountered remarkable success in clinic [9] [10] [11] . However, the high price (over 100,000 USD per year per patient) of these treatments and their ineffectiveness for a significant fraction of patients hamper a wider clinical application [12] .
The improvement of immune-based cancer treatments is challenging because novel medical approaches often fail in clinical trials despite their feasibility in mouse cancer models. An incomplete understanding of the immune functions as a barrier to tumor formation and growth may be one of the reasons for these failures. Certainly, murine models provide tremendous insights into tumor immunity processes. However, it is fair to say that certain immune responses specific to mice are not mirrored in humans and may distort the interpretations of curative treatments. Because of the complexities of immune systems, often driven by rapid evolution and species-specific adaptations, focusing tumor immunity research only on one animal model may be precarious. To bridge the gaps in our understanding of tumor immune responses across multiple species, nonmammalian animal models, such as the zebrafish (Danio rerio) or African clawed frog (Xenopus laevis) have an important role to play.
Given that during evolution advantageous mechanisms are often conserved, it is plausible to postulate that crucial molecular and cellular mechanisms involved in tumor immune responses should be found across all vertebrates. Conversely, certain features of, and processes in, tumor immunity may have evolved only in certain species, possibly reflecting species-specific adaptations. A comparative approach using genetically distant species provides an opportunity for distinguishing similarities from differences, which can help predicting the applicability of novel immunotherapeutic approaches to humans.
Here, we review current evidence supporting the relevance of alternative animal models to study the interactions between tumor and immune cells. As tumor immunity in the amphibian X. laevis has been extensively characterized and has potential for providing deeper insights, we would like to propose X. laevis as a research platform to compare and contrast vertebrate immune responses against cancers.
Integrating Nonmammalian Models for Studying Defenses Against Tumors
The occurrence of tumors and cancers from invertebrates to vertebrates has been reviewed in detail elsewhere [1, 13, 14] . Collectively, these reports provide evidence for a great variety of tumors, not only originating from different tissues but also resulting from different causes (e.g., exposure to carcinogenic chemicals, viral infection, inherited genetic defects). This diversity of tumor types implies that most species studied to date are susceptible to tumors and cancers. The commonality of cancer diseases is also underscored by the evolutionary conservation of many molecular pathways involved in tumor transformation. These include the homologs of the tumor suppressor gene tp53, mutations in which are involved in most of human cancers, and are also found in other multicellular organisms [15, 16] . The wide diversity of organism affected by cancer provides an opportunity to gather novel insight into control mechanisms and immune defenses.
In invertebrates, very low tumor incidences in caught species of crustacean decapods including crayfish, crabs, lobster, prawns, and shrimps, have been observed in commercial fisheries [17] . Although to date it is unclear how or if crustacean decapods are inherently tumor resistant, studying these species in more details can lead to the discover of new efficient anticancer defenses. Sea urchins, a key research tool for developmental biology, recently have been adapted as model organisms in cancer biology. Initial studies have shown that sea urchin genomes efficiently withstand ultraviolet-and hydrogen peroxideinduced DNA damage that often leads to cancer formation in animal models [18, 19] . Although ongoing studies in the sea urchin mainly focus on DNA repair mechanisms, an interesting aspect in Lytechinus variegatus concerns the expression of certain innate immune genes (including those involved in NF-κB signaling) that are markedly upregulated following methyl methanesulfonate-induced DNA damage [20] . These findings underline the evolutionary conservation of genes and interactions between cancerous and immune cells.
In jawed vertebrates, zebrafish are another alternative tumor model to mice and have become a valuable experimental platform. It is worth noting that the zebrafish model offers a wide panel of tumor types that share many similarities with their mammalian counterparts [21] . Owing to its rapid development, small body size, and great fecundity, zebrafish have been used in high-throughput screens either for discovering molecules and pathways driving tumorigenesis or for identifying potential curative drugs against cancers [21] . Moreover, the generation of transplantable tumor cell lines in clonal zebrafish provides an opportunity to study tumor and immune cell interactions in vivo [22, 23] . With the aid of intravital microscopy and transgenic lines with fluorescent reporters, labeling either tumor cells or specific immune cell populations, zebrafish have provided real time insights into how innate immune cells such as macrophages and neutrophils contribute to the processes of tumor initiation and metastasis [24-26•] .
Among other alternative models, the amphibian Xenopus, with its two different species: X. tropicalis and X. laevis, has been gaining momentum in biomedical research in general and cancer research in particular. Initially, Xenopus has assisted in the discovery of conserved functions and signaling pathways of many tumor suppressor genes and protooncogenes [28] . Notably, the role of gli1 as a protooncogene driving basal cell carcinoma, was proposed based on Xenopus data, then confirmed in mouse cancer models and finally in cancer patients [28, 29] . The contributions made in Xenopus resulted in gli1 being used as a prognostic biomarker for the disease, underlying how basic research in lower animals can impact human health [30] .
An innovative application in Xenopus is the use of healthy embryos for initial anticancer drug screens, which subsequently are tested in mouse cancer models [31•] . In this method, beneficial drugs are identified based on whether they disrupt normal development and thus may also have some anticancer properties. Using this approach, the researchers were able to successfully identify and test drugs that disrupt cancer cell proliferation and metastasis [31•] . However, it would be advantageous to also screen prospective drugs on specific tumor types or to gain more insights on their specificity and potency.
Although a range of spontaneous tumors have been described in Xenopus over the years, from hepatomoa, teratoma, renal carcinoma, fibroma, fibrosarcoma, ovarian dysgerminoma, melanophoroma, lymphoma (reviewed in [1, 32] ) to pancreatic carcinoma [33] , deriving tumor cell lines, crucial for tumor immunity studies, has been met with limited success. A notable exception, however, is isolation and characterization of several transplantable lymphoid tumor lines that were derived from spontaneous thymic tumors [34] .
There have been only a few reported attempts with limited success in Xenopus to induce cancers with potent carcinogens, such as N-dimethylnitrosamine or N-methyl-N-nitrosourea that in mice cause DNA damage [35, 36] . The reasons for this are not really clear but it is possible that these chemicals are not as potent in Xenopus (L. DuPasquier, personal comm.). In contrast, reverse genetic approaches to induce tumors in Xenopus have achieved considerable success. For example, the generation of tumors in Xenopus by overexpression of proto-oncogenes such as gli1, kras
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Trp24 canleadtothe formationof hyperplastic tumor-like structures, which could be predicted and restrained by the state of transmembrane voltage potential [27, 37] . Interestingly, using optogenetics to control ion channels and proton pumps by light, it is possible to manipulate the voltage potential and thus affect the formation of these tumor-like structures [38••] . However, these tumor-like structures only occur during early developmental stages and lack a defined histopathology. It is also not clear whether these structures are invasive tumors or transplantable between individual tadpoles and adults.
Recent developments of more sophisticated genome engineering techniques, such as transcriptional activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic and associated protein 9 nuclease (CRISPR/Cas9), allow researchers to precisely target and mutate any gene candidate involved in diseases including cancers and in tumor immunity [39] . Xenopus genome sequences as well as detailed information and extensive resources can be accessed on Xenbase online (http://www.xenbase.org/entry/). The introduction of mutations by genome editing to disrupt specific Xenopus genes makes it possible to recapitulate phenotypes of certain human diseases, including cancers [42, 43•, 44•] . For example, TALENsmediated disruption of the tumor suppressor gene adenomatous polyposis coli apc gene in X. tropicalis was reported to lead to familial adenomatous polyposis similar to mouse and human intestinal cancers [43•] . Also, akin to pediatric tumors of retina, double knockouts of the retinoblastoma 1 (rb1) and retinoblastoma-like 1 (rbl1) by CRISPR/Cas9 technology initiated retinoblastoma in X. tropicalis [44•] . The exploration of novel anticancer drugs will surely be facilitated with the TALENs-and CRISPR-induced tumors. Taking into account the small size of Xenopus as well as its simple and costeffective husbandry requirements, the engineered tumors in Xenopus are likely to serve as attractive preclinical models for high throughput drug discovery screens.
MHC Class I and Class I-Like Molecules in Tumor Immunity
Comparative approaches using nonmammalian animal models are useful for gathering new insights into conserved molecular mechanisms driving tumorigenesis. One could also speculate that in general the immune responses to tumors are conserved as well. Among nonmammalian models presently available, inbred and clonal lines in X. laevis hold promise for further elucidating the interactions between tumors and the host immune system, especially, the perplexing roles of MHC molecules and innate (i)T cells in tumor immunity.
In jawed vertebrates, major histocompatibility complex (MHC) class I molecules are central to immune function in general and to tumor immunity in particular. Being expressed on a cell surface, MHC class I molecules constitute an interface for the immune system to receive information about the functional status of a cell, whether being normal, infected by pathogens, stressed, or cancerous. The general structure of MHC class I molecules is composed of three immunoglobulin alpha domains, anchored by a transmembrane region and a cytoplasmic tail, and typically associated with beta-2 microglobulin. Tumor-derived antigens are presented by MHC class I molecules in order to elicit immune responses [45, 46] .
Based on the number of alleles, genomic location, and expression patterns, MHC class I genes are subdivided into classical, nonclassical MHC class I, and MHC class-I like. Whereas classical MHC class I genes are characterized by their high polymorphism and ubiquitous expression, the other members are typically oligomorphic and expressed only in certain tissues. In contrast to MHC class I-like genes, both classical and nonclassical MHC class I reside in the MHC locus. Interestingly, the three kinds of MHC molecules, classical, nonclassical MHC class I and class I-like, are increasingly associated with disparate roles in tumor immunity.
As tumors progress and become metastatic, they often down regulate the expression of classical MHC class I molecules [47] . This process, which can be driven by multiple mechanisms, allows the tumor to avoid immune recognition and destruction [48] . In contrast, the tumor-related expression patterns of nonclassical and class I-like are often contradictory, where depending on a tumor type, the particular gene is either unchanged, upregulated, or downregulated [49] . For example, the expression of the human nonclassical MHC HLA-G can be correlated with positive outcomes and even tumor regression in certain but not other cancer types [50] . Another example is CD1d that can be associated with either promoting [51] or suppressing antitumor responses [52] . Togainabetterunderstandingofthecomplexrolesofnonclassical classIandclassI-likegenesintumorimmunity,analternativemodel organism suchas X.laevishasproventobehelpful.Inadditiontoa single classical MHC class I gene pergenome, X. laevis has a large family of MHC class I-like genes (mhc1b or previously known as XNC),whichareclustered outsidetheMHClocus [53, 54] .mhc1b genes encode molecules with the typical three immunoglobulin α domain structure, exhibit low polymorphism, and in general have limited tissue distribution [53, 55] . For example, one of the mhc1b genes,mhc1b10.L(previouslynamedXNC10;GenBankaccession fj589642.1, L chromosome location 74758590-74773706 on version9.1),ishighlyexpressedinthespleenandthymusbutnotother tissues [55] .Acommoncharacteristicattributedtomanyvertebrate MHCclassI-likegenesislowsequenceidentityconservation,even acrosscloselyrelatedspecies [45, 56] .Therefore,findingthatX.laevis andX.tropicalis,whosespeciessplitfromacommonancestorabout 45millionyearsago,shareahighdegreeofsimilaritiesintheirmhc1b genes(48-95%forα1,54-95%forα2,and74-99%forα3domains) isremarkable [41••,53,55] .
Even more interesting is that at least one of the mhc1b genes-mhc1b10.L-is highly conserved among ten other Xenopodinae subfamily species that have different genome ploidy (ranging from di-to dodecaploidy) [53] . Although the mhc1b10.L gene shares no true orthology with any mammalian nonclassical/class I-like genes, it is required for the development and function of innate T cells, suggesting a functional analogy to the mammalian class I-like cd1d gene [57••] .
Tumor Immunity in Xenopus
Extensive research has established that the innate and adaptive immunity between Xenopus and mammals is highly conserved (reviewed in [58] ). Furthermore, key advances in Xenopus research and tool development have been made over the years including the generation of inbred and cloned Xenopus lines, the production of a range of Xenopus-specific monoclonal antibodies, the characterization of transplantable lymphoid tumors, the X. laevis genome sequencing and annotation, and the adaptation of reverse genetic techniques. This serves as the foundations for current tumor immunity research in Xenopus (Fig. 1) .
In all jawed vertebrates, immune tolerance of organ, tissue, or even tumor transplantations requires a match between the MHC molecules of donors and recipients [59] . To prevent tumor graft rejection, it is possible to compromise the recipient's immune system by administrating either immunosuppressive drugs or lethal gamma-irradiation. However, these methods hardly allow studying any valuable interactions between immune systems and tumors as the immune system is considerably suppressed. To circumvent this limitation, inbred MHC-defined strains (F) and X. laevis/X. gilli isogenic clones (LG-15, or LG-6) were generated, which permit tumor grafts from donor to recipient and from tumor cell culture to recipient without the interference of transplant rejection [34, 60, 61] . It is noteworthy that inbred F and LG cloned animals are available in the Xenopus Leavis Research Resources ( h t t p s : / / w w w. u r m c . r o c h e s t e r. e du / m i c r o b i ol o g yimmunology/xenopus-laevis.aspx).
Another milestone in Xenopus tumor immunity studies was set by deriving and characterizing several lymphoid tumor cell lines from spontaneous thymic tumors [34, 62] . Since then, these tumors have been adapted to cell culture conditions, tested for their molecular signatures and immune-related responses in vitro and in vivo [34, 62] . The characteristics of these tumor lines have been reviewed in detail [1, 63] . Here, it is worth mentioning that, due to their thymic origins and molecular profiles, these tumors resemble rare types of leukocytic leukemias. As natural models for studying human cancer and immune-related pathologies are hard to come by, the availability of Xenopus tumor cell lines is particularly valuable in dissecting the events that lead and contribute to such pathologies.
A notable feature of these Xenopus lymphoidtumor celllines is their different capacity to grow in vivo, despite their similar molecular phenotypes. One of the four tumor lines, the ff-2 tumor grows slowly but progressively following transplantation into syngeneic tadpoles of the F genetic background, whereas it is rejected in a T cell-dependent manner in the F adults. In contrast, transplanted 15/0 tumor cells proliferate quickly and aggressively regardless of developmental stage in both LG-6 and LG-15 clones, which share the same heterozygous MHC haplotype (a/c) but differ at multiple minor histocompatibility (H) loci [33, 62] . These different degrees of tumor invasiveness can be accounted to different properties of the tadpole and adult immune systems and/or different MHC expression profiles of these tumors. For instance, the ff-2 tumor cells express both classical MHC class I (mhc1a) and mhc1b genes, whereas the 15/0 tumors onlyexpressmhc1bs.Outof 21 mhc1bgenes,boththe ff-2and15/ 0 express mhc1b1, mhc1b4, mhc1b10, and mhc1b11 (previously named XNC1, XNC4, XNC10, and XNC11; Banach and Robert, unpublished observations).
Throughout the years, immune cells and mechanisms involved in the tumorigenesis of 15/0 and ff-2 tumors have been investigated [1] . One of the recent refinements in these experiments was the adaptation of a semi-solid tumor model [64] . Previously, Xenopus tumor cells were transplanted into the peritoneal cavity of a tadpole. While the tumor growing as ascites is convenient for retrieving significant numbers of cells, the peritoneal cavity with its opaque layer of iridophores prevents direct visualization of interactions between tumor and immune cells by intravital microscopy. To circumvent these limitations, a semi-solid tumor model was developed, in which otherwise nonadherent and single tumor cells are embedded in rat collagen fibers [64] . Both tumor containing collagen and empty collagen (for an internal control) can be easily transplanted on top of a tadpole's head under the transparent skin. Interestingly, the disorganized and leaking neovasculature, typical to mammalian tumors was also observed in our semi-solid tumor grafts within days after transplantations [64] . Thus, this model system recapitulates early tumor vascularization that often aids in tumor growth. Of particular relevance is to determine whether macrophages and innate T cells infiltrate semi-solid tumor grafts as they do following intraperitoneal transplantation [65] .
The initial hypothesis of the critical involvement of mhc1b genes in tumorigenesis was not formally tested until the adaptation of RNA interference technology to Xenopus [66, 67] . Global and stable silencing of mhc1b genes in 15/0 tumors, using a consensus shRNA targeting the α3 domain, increased their tumorigenecity in vivo, which correlated with their enhanced resistance to in vitro killing by unconventional cytotoxic T cells [66] . It was also observed that XNC-silenced 15/0 tumors were more susceptible to natural killer (NK) killing, although NK cells were insufficient to prevent the in vivo tumor growth [66] . Interestingly, NK cells were also found to be cytotoxic to ff-2 tumor cells; however, it is still unknown whether mhc1b genes are involved in this mechanism [68] . Surprisingly, unlike the global mhc1b silencing, specifically targeting mhc1b10.L in 15/0 tumor cells, resulted in an acute tumor rejection by the immune system of syngeneic tadpoles by a process involving cell-mediated toxicity [65] . This study further supports the hypothesis that the expression of different mhc1b genes would confer disparate tumor outcomes, either promoting tumor growth or enhancing eradication of tumor cells.
To gain a better understanding about the nature of immune cells interacting with XNC10 molecules encoded by the mhc1b10.L gene, a molecular tool-XNC10-tetramer-which is a synthetic protein comprising four recombinant MHC class Ilike molecules fused with beta-2 microglobulin, was developed for the first time outside mammals [57••] . These XNC10-tetramers allowed characterization of a specific innate-like T (iT) cell population interacting with XNC10 [57••] .
Innate T Cells in Mammals and Xenopus
Recently, iTcells have emerged as intriguing immune cells as they exhibit characteristics of both innate and adaptive immune cells. In mammals, some iTcell populations are known as natural killer T (NKT) cells because they express natural killer cell markers. Reminiscent of innate immune functions is the ability of NKT cells to rapidly produce a range of pro-and anti-inflammatory cytokines, often within hours after stimulation and without cell expansion. Similar to conventional T cells, NKT cells express a specific Tcell receptor (TCR), which interacts with a MHC class I molecule on another cell. Unlike conventional TCRs, which interact with a peptide bound to MHC class I molecule, the TCR of [71] .
The tumor-killing properties of human type I NKT cells were also tested in clinical trials and some cancer patients experienced disease stabilization and prolonged survival; however, often without significant tumor regression [72] . These incomplete results should not discourage the development of the next generation of type I NKT cell-based cancer therapies as the current treatment may be based on insufficient knowledge. For example, the frequencies of type I NKT cells between mouse and humans are strikingly different and high variability among individuals is common [73] . Moreover, most human cancers develop over years during which time immune cell effectors including type I NKT cells are likely to be exhausted, suppressed, and/ or significantly reduced in numbers.
Although XNC10 and XNC10-restricted iT cells represent an analogy or convergence to mammalian CD1d and NKT cells, the study of this system may provide useful clues about iT cell functions in tumors. Interestingly, similar to their mammalian counterparts, XNC10-restricted iT cells could be also subdivided into type I and II based on TCR αβ repertoire and CD8 surface expression [57••] . Type I XNC10-restricted iT cells are CD8 negative and express an invariant TCRα rearrangement (Vα6-Jα1.43) coupled with a limited TCRβ chain repertoire. Reminiscent of mammalian type II NKT cells, Xenopus type II XNC10-restricted iT cells have a broader TCR αβ repertoire and express CD8α at a low level [57••] . In the context of tumor immunity, our preliminary data suggests that type I and type II XNC10-restricted iT cells may have opposing functions in tumor immunity [65] .
Deep sequencing analysis of TCRα repertoire in Xenopus tadpoles has revealed that apart from Vα6-Jα1.43 iT cells known to interact with XNC10, there is five other predominant TCRα, suggesting additional iT cell subsets [57••] . Recently, we started to investigate the involvement of these other iTcells following the ff-2 tumor transplantation. As iT cells are considered to be fast responders, we collected the tumor and infiltrating cells from the peritoneal cavity within the first 3 days after transplantation. In addition to the expected infiltration of XNC10-restricted iT cells expressing the invariant Vα6-Jα1.43, we also detected another invariant TCRα rearrangement (Vα22-Jα1.32), suggesting the infiltration of another iT cell subset (Banach and Robert, unpublished data). Our working model of iT cell involvement in tumor immunity in Xenopus is depicted in Fig. 2 . Vα6-Jα1.43 iT cells either directly or indirectly via macrophages interact with the tumor cells. The expression of XNC10 by tumor cells suppresses the cytotoxicity of Vα6-Jα1.43 iT cells. The restricting element for theVα22-Jα1.32iTcell subset is currentlyunknown, and how this population interacts with the tumor cells is under investigation. Apart from XNC10, the ff-2 tumor highly expresses XNC1, XNC4, and XNC11 genes. Thus, we are in the process of generating ff-2 tumor cell lines deficient for each of these molecules using the CRISPR/Cas9 technology in order to determine whether XNC1-, XNC4-, or XNC11-deficient ff-2 still elicit the infiltration of Vα22-Jα1.32 iT cells.
Conclusions
Studying immune responses against tumors and cancers through the narrow lens of mammalian species limits our understanding of evolutionary conserved functions and speciesspecific characteristics. Among many valuable nonmammalian species, X. laevis has recently gained momentum in tumor immunity research. MHC-defined inbred and cloned animals, several well-characterized tumor cell lines, and effective antibodies and tetramers enabled initial studies to gather information about XNC genes and iT cells in the context of tumor immunity. With the emergence of novel genome editing techniques, such as TALENs and CRISPR/Cas9, and availability of fully sequenced and annotated genomes, efficient loss-offunction approaches can be implemented to investigate the roles of mhc1bs (XNCs) and iT cells in tumor immunity. As different immune cell subsets may either prevent or support tumor growth, we propose that only some and not other XNC molecules and iT cells are beneficial. It is also possible that due to ff-2 or 15/0 tumor cells some of these immune responses may be nonfunctional or perturbed, similarly to maladjusted responses found in mammalian cancers. With the fresh approach of using alternative models, X. laevis can confirm existing, or help the discovery of novel, mechanisms governing the tumor and immune system interactions.
